Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia

Eur J Haematol. 2023 Mar;110(3):330-331. doi: 10.1111/ejh.13907. Epub 2022 Dec 13.

Authors

Mario Tiribelli^{1

2}, Eleonora Toffoletti^{1

2}, Sara Di Giusto¹, Renato Fanin^{1

2}, Daniela Damiani^{1

2}

Affiliations

¹ Division of Hematology and Bone Marrow Transplantation, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
² Department of Medical Area, University of Udine, Udine, Italy.

PMID: 36458956
DOI: 10.1111/ejh.13907

No abstract available

Publication types

Letter

MeSH terms

Chronic Disease
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
Leukemia, Myeloid*
Protein Kinase Inhibitors / adverse effects
Tyrosine Kinase Inhibitors

Substances

Tyrosine Kinase Inhibitors
Protein Kinase Inhibitors